Literature DB >> 17714823

Type of antidepressant therapy and risk of type 2 diabetes in people with depression.

Lauren C Brown1, Sumit R Majumdar, Jeffrey A Johnson.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the differential risk of diabetes among people with depression taking antidepressant therapy.
METHODS: A nested case control design was used to investigate the study objective. Data from the Canadian province of Saskatchewan was available from January 1, 1991 to December 31, 2001; the average length of follow-up was 4.07 years. Type 2 diabetes was identified based on ICD-9 diagnostic codes and antidiabetic medication prescriptions; prior depression was ascertained based on ICD-9 diagnostic codes and antidepressant prescriptions.
RESULTS: Multivariate logistic regression analysis was used to estimate the odds ratio (OR) and 95% confidence intervals (CI). We identified 2391 individuals with incident depression treated with antidepressant therapy. The mean age was 53.6 (S.D.: 16.4) and 68% were female. After multivariate adjustment, the concurrent use of selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA) was associated with a significantly increased risk of type 2 diabetes (adjusted OR: 1.89; 95% CI: 1.35-2.65).
CONCLUSIONS: Concurrent use of TCA and SSRI was associated with an increased risk of developing type 2 diabetes compared to using TCA alone. Individuals taking combination TCA and SSRI therapy should be closely monitored for development of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714823     DOI: 10.1016/j.diabres.2007.07.009

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  31 in total

1.  Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity.

Authors:  Jing Liu; Ming Guo; Di Zhang; Shao-Ying Cheng; Meilian Liu; Jun Ding; Philipp E Scherer; Feng Liu; Xin-Yun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

3.  High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice.

Authors:  Juliane Zemdegs; Gaël Quesseveur; David Jarriault; Luc Pénicaud; Xavier Fioramonti; Bruno P Guiard
Journal:  Br J Pharmacol       Date:  2015-12-09       Impact factor: 8.739

Review 4.  Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports.

Authors:  Star Khoza; Jamie C Barner
Journal:  Int J Clin Pharm       Date:  2011-04-13

5.  Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case-control study.

Authors:  Star Khoza; Jamie C Barner; Thomas M Bohman; Karen Rascati; Kenneth Lawson; James P Wilson
Journal:  Int J Clin Pharm       Date:  2012-01-18

6.  Metabolic Effects of Antidepressant Treatment.

Authors:  Özlem Olguner Eker; Saliha Özsoy; Baki Eker; Hatice Doğan
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

Review 7.  [Depression and diabetes mellitus type 2].

Authors:  M Deuschle; U Schweiger
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

8.  The association between antidepressant use and glycemic control in the Southern Community Cohort Study (SCCS).

Authors:  Jamie R Kammer; Akiko S Hosler; Emily Leckman-Westin; Greg DiRienzo; Chandra Y Osborn
Journal:  J Diabetes Complications       Date:  2015-11-11       Impact factor: 2.852

9.  Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study.

Authors:  Richard R Rubin; Yong Ma; Mark Peyrot; David G Marrero; David W Price; Elizabeth Barrett-Connor; William C Knowler
Journal:  Diabetes Care       Date:  2010-08-30       Impact factor: 19.112

10.  Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans.

Authors:  Hedvig Bennet; Inês G Mollet; Alexander Balhuizen; Anya Medina; Cecilia Nagorny; Annika Bagge; Joao Fadista; Emilia Ottosson-Laakso; Petter Vikman; Marloes Dekker-Nitert; Lena Eliasson; Nils Wierup; Isabella Artner; Malin Fex
Journal:  Diabetologia       Date:  2016-01-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.